OSI starts phase 3 trial of Tarceva in non-small cell lung cancer

By Lisa Kerner

Charlotte, N.C., Sept. 21 - OSI Pharmaceuticals, Inc. began a phase 3 clinical trial of Tarceva (erlotinib) as a targeted adjuvant therapy in patients who have undergone surgery for non-small cell lung cancer with EGFR-positive tumors.

About 945 patients will be enrolled in the international, multi-center, placebo-controlled study, according to the Melville, N.Y., pharmaceutical company.

The primary objective of the two-year study is to evaluate the oral, once-daily medication in prolonging disease-free survival.

OSI is developing and commercializing Tarceva in collaboration with Genentech, Inc. and Roche.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.